search
Back to results

RegoNivo vs Standard of Care Chemotherapy in AGOC (INTEGRATEIIb)

Primary Purpose

Gastro-Oesophageal Cancer

Status
Recruiting
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
Regorafenib
Nivolumab
Docetaxel
Paclitaxel
Irinotecan
Trifluridine/Tipracil
Sponsored by
Australasian Gastro-Intestinal Trials Group
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Gastro-Oesophageal Cancer focused on measuring Metastatic, Locally recurrent, Oesophago-gastric junction, Stomach, Adenocarcinoma, Undifferentiated carcinoma, RegoNivo

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Adults (18 years or over) with metastatic or locally recurrent gastro-oesophageal cancer which:

    1. has arisen in any primary gastro-oesophageal site (oesophago-gastric junction (GOJ) or stomach); and
    2. is of adenocarcinoma or undifferentiated carcinoma histology; and
    3. is evaluable according to Response Evaluation Criteria in Solid Tumours (RECIST Version 1.1) by computed tomography (CT) scan performed within 21 days prior to randomisation. A lesion in a previously irradiated area is eligible to be considered as measurable disease as long as there is objective evidence of progression of the lesion prior to study enrolment; and
    4. has failed or been intolerant to a minimum of 2 lines of prior anti-cancer therapy for recurrent/metastatic disease which must have included at least one platinum agent and one fluoropyrimidine analogue. Note: Neoadjuvant or adjuvant chemotherapy or chemoradiotherapy will be considered as first line treatment where people have relapsed or progressed within 6 months of completing treatment; Radiosensitising chemotherapy given solely for this purpose concurrent with palliative radiation will not be considered as a line of treatment. Ramucirumab monotherapy, or immunotherapy with a checkpoint inhibitor, will be considered a line of treatment.
    5. HER2-positive participants must have received trastuzumab
  2. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1 (Appendix 1).
  3. Ability to swallow oral medication.
  4. Adequate bone marrow function (Platelets ≥100x109/L; Absolute Neutrophil Count (ANC) ≥1.5x109/L and Haemoglobin ≥ 9.0g/dL).
  5. Adequate renal function (Creatinine clearance >50 ml/min) based on either the Cockcroft-Gault formula (Appendix 2), 24-hour urine or Glomerular Filtration Rate (GFR) scan; and serum creatinine ≤1.5 x Upper Limit of Normal (ULN).
  6. Adequate liver function (Serum total bilirubin ≤1.5 x ULN, and INR ≤ 1.5 x ULN, and Alanine aminotransferase (ALT), Aspartate aminotransferase (AST), Alkaline phosphatase (ALP) ≤2.5 x ULN (≤ 5 x ULN for participants with liver metastases)).

    Participants being treated with an anti-coagulant, such as warfarin or heparin, will be allowed to participate provided that no prior evidence of an underlying abnormality in these parameters exists.

  7. Willing and able to comply with all study requirements, including treatment, timing, and/or nature of required assessments and follow-up.
  8. Study treatment both planned and able to start within 7 days after randomisation (note: subjects randomised on a Friday should commence treatment no earlier than the following Monday)
  9. Signed, written informed consent

Exclusion Criteria:

  1. Known allergy to the investigational product drug class or excipients in the regorafenib and/or nivolumab
  2. Poorly-controlled hypertension (systolic blood pressure >140mmHg or diastolic pressure> 90mmHg despite optimal medical management).
  3. Participants with known, uncontrolled malabsorption syndromes
  4. Any prior anti-VEGF targeted therapy using small molecule VEGF TKIs (e.g. apatinib). Prior anti-VEGF targeted monoclonal antibody therapies (e.g. bevacizumab and ramucirumab) are permitted.
  5. Any prior use of more than one immune checkpoint inhibitor
  6. Treatment with any previous drug therapy within 2 weeks prior to first dose of study treatment. This includes any investigational therapy.
  7. Use of biological response modifiers, such as granulocyte colony stimulating factor (G-CSF), within 3 weeks prior to randomisation.
  8. Concurrent treatment with strong CYP3A4 inhibitors or inducers.
  9. Palliative radiotherapy, unless more than 14 days have elapsed between completion of radiation and the date of registration, and adverse events resulting from radiation have resolved to < Grade 2 according to CTCAE V5.0
  10. Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to randomization
  11. Arterial thrombotic or ischaemic events, such as cerebrovascular accident, within 6 months prior to randomization.
  12. Venous thrombotic events and pulmonary embolism within 3 months prior to randomization
  13. Any haemorrhage or bleeding event ≥ Grade 3 according to CTCAE v5.0 within 4 weeks prior to randomization.
  14. Non-healing wound, ulcer, or bone fracture.
  15. Interstitial lung disease with ongoing signs and symptoms
  16. Clinical hyperthyroidism or hypothyroidism. Note: non-clinically significant abnormal TFTs (abnormal TSH and abnormal T3 and/or abnormal T4) considered to be due to sick euthyroid syndrome is allowed.
  17. Persistent proteinuria of ≥ Grade 3 according to CTCAE v5.0 (equivalent to > 3.5g of protein over 24 hour measured on either a random specimen or 24 hour collection.
  18. Uncontrolled metastatic disease to the central nervous system. To be eligible, known CNS metastases should have been treated with surgery and/or radiotherapy and the patient should have been receiving a stable dose of steroids for at least 2 weeks prior to randomization, with no deterioration in neurological symptoms during this time.
  19. History of another malignancy within 2 years prior to randomization. Participants with the following are eligible for this study:

    1. curatively treated cervical carcinoma in situ,
    2. non-melanomatous carcinoma of the skin,
    3. superficial bladder tumours (T1a [Non-invasive tumour], and Tis [Carcinoma in situ]),
    4. treated thyroid papillary cancer
  20. Any significant active infection, including chronic active hepatitis B, hepatitis C, or HIV. Testing for these is not mandatory unless clinically indicated. Participants with known Hepatitis B/C infection will be allowed to participate providing evidence of viral suppression has been documented and the patient remains on appropriate anti-viral therapy.
  21. Patients with acute coronary syndrome (including myocardial infarction and unstable angina), and with a history of coronary angioplasty or stent placement performed within 6 months before enrolment
  22. Patients with a ≥ grade 3 active infection according to CTCAE version 5.0
  23. Patients with concurrent autoimmune disease, or a history of chronic or recurrent autoimmune disease
  24. Patients who require systemic corticosteroids (excluding temporary usage for tests, prophylactic administration for allergic reactions, or to alleviate swelling associated with radiotherapy; if used as replacement therapy e.g. ≤ 10 mg prednisolone or dexamethasone ≤ 2 mg per day) or immunosuppressants, or who have received such a therapy < 14 days prior to randomisation
  25. Patients with a seizure disorder who require pharmacotherapy
  26. Serious medical or psychiatric condition(s) that might limit the ability of the patient to comply with the protocol.
  27. Pregnancy, lactation, or inadequate contraception. Women must be post-menopausal infertile, or use a reliable means of contraception. Women of childbearing potential must have a negative pregnancy test done within 7 days prior to randomization. Men must have been surgically sterilized or use a barrier method of contraception.

Sites / Locations

  • Mayo Clinic ArizonaRecruiting
  • USC NorrisRecruiting
  • Siouxland Regional Cancer CenterRecruiting
  • Monument Health Rapid City HospitalRecruiting
  • Fred Hutchinson Cancer Research Centre - South Lake Union ClinicRecruiting
  • Coffs Harbour Health CampusRecruiting
  • Concord Repatriation General HospitalRecruiting
  • St Vincent's Public HospitalRecruiting
  • Border Medical Oncology Research UnitRecruiting
  • Gosford HospitalRecruiting
  • St George HospitalRecruiting
  • Newcastle Private HospitalRecruiting
  • Port Macquarie Base HospitalRecruiting
  • Prince of Wales HospitalRecruiting
  • Royal North Shore Private HospitalRecruiting
  • The Tweed HospitalRecruiting
  • Ballarat Oncology and Haematology ServicesRecruiting
  • Westmead HospitalRecruiting
  • Royal Darwin HospitalRecruiting
  • The Townsville HospitalRecruiting
  • Royal Brisbane and Womens HospitalRecruiting
  • Sunshine Coast University HospitalRecruiting
  • The Queen Elizabeth HospitalRecruiting
  • Flinders Medical CentreRecruiting
  • Royal Hobart HospitalRecruiting
  • Monash HealthRecruiting
  • Austin HealthRecruiting
  • Sir Charles Gairdner HospitalRecruiting
  • St John of God Hospital SubiacoRecruiting
  • Landeskrankenanstalten-Betriebsgesellschaft-KABEG
  • Ordensklinikum Linz GmbH Barmherzige schwestern
  • Medizinische Universitaet Wien
  • Landesklinikum Wiener Neustadt
  • Evang. Klinikum Bethel BielefeldRecruiting
  • Helios Bad SaarowRecruiting
  • Klinikum BayreuthRecruiting
  • Charité Universitätsmedizin BerlinRecruiting
  • Universitätsklinikum Bonn
  • KEM/Evang. Kliniken Essen Mitte gGmbHRecruiting
  • Institut für Klinisch Onkol Forschung am Krankenhaus NordwestRecruiting
  • Universitätsklinikum Greifswald
  • Norddeutsches Studienzentrum für Innovative Onkologie (NIO)Recruiting
  • Universitätsklinikum HeidelbergRecruiting
  • Universitätsklinikum JenaRecruiting
  • Kliniken der Stadt KölnRecruiting
  • Universitätsklinikum LeipzigRecruiting
  • Klinikum Leverkusen gGmbHRecruiting
  • Klinikum LudwigburgRecruiting
  • Klinikum Magdeburg gGmbHRecruiting
  • Universitätsklinikum MainzRecruiting
  • Philipps-Universitat MarburgRecruiting
  • Klinikum rechts der Isar der TU MünchenRecruiting
  • Studienzentrum Onkologie RavensburgRecruiting
  • Caritas Klinikum Saarbrücken St. TheresiaRecruiting
  • Universitätsklinikum UlmRecruiting
  • Istituto Nazionale Tumori di Napoli-IRCCS Fondazione G. Pascale
  • Universitae degli studi della Campania "Luigi Vanvitelli"
  • Azienda USL-IRCCS Di Reggio Emilia
  • San Camillo Forlanini Hospitals
  • Universita Cattolica del Sacro Cuore, University Hospital Gemelli
  • IRCCS Fondazione Casa Sollievo della Sofferenza
  • National Cancer Centre Hospital EastRecruiting
  • Hokkaido University HospitalRecruiting
  • Kyushu Cancer CenterRecruiting
  • Shikoku Cancer CenterRecruiting
  • Saitama Cancer CenterRecruiting
  • Shizuoka Cancer CenterRecruiting
  • Hallym University Sacred Heart Hospital
  • Dong-A University Hospital
  • Haeundae Paik Hospital
  • Chungbuk National University Hospital
  • Jeonbuk National University Hospital
  • Gyeongsang National University Hospital
  • Asan Medical Centre
  • Chung-Ang University Hospital
  • Kangbuk Samsung Hospital
  • Korea University Anam Hospital
  • Korea University Guro Hospital
  • Seoul National University Bundang Hospital
  • Seoul National University Hospital
  • SMG-SNU Boramae Medical Center
  • The Catholic University of Korea - Seoul St. Mary's Hospital
  • The Catholic University of Korea - Yeouido St. Mary's Hospital
  • Yonsei University Health System - Gangnam Severance Hospital
  • Yonsei University Health System - Severance Hospital
  • Vall d'Hebron University Hospital
  • Hospital Universitario de Navarra
  • Hospital Clinico Universitario De Valencia
  • Kaohsiung Medical University Chung-Ho Memorial HospitalRecruiting
  • China Medical University Hospital (CMUH)Recruiting
  • National Cheng Kung University HospitalRecruiting
  • National Taiwan University Hospital (NTUH)Recruiting
  • Taipei Veterans General Hospital (TPVGH)

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

RegoNivo

Standard of Care

Arm Description

Participants in the RegoNivo arm will; self-administer 90mg (3x30mg) of regorafenib days 1-21 of each 28-day treatment cycle and; receive intravenous nivolumab 240 mg day 1 of each 14 day cycle until disease progression or prohibitive adverse events as per protocol, given in hospital by infusion. After 2 months, patients whose disease is controlled may have nivolumab administered 480 mg every 28 days.

Participants in the control arm will receive investigator choice chemotherapy with any of the following agents taxane (paclitaxel or docetaxel) irinotecan or oral trifluridine/tipiracil (TAS102) All treatment groups will receive Best Supportive Care (BSC).

Outcomes

Primary Outcome Measures

O/S
To determine the effect of RegoNivo on overall survival (OS) (death from any cause) in the overall study population and in the Asian sub-population.

Secondary Outcome Measures

Determine the effect of RegoNivo on; PFS
Progression free survival (PFS)(disease progression or death) in the study population
Determine the effect of RegoNivo on; OTRR
Objective tumour response rate (OTRR)((partial or complete response (PR or CR)) according to Response Evaluation Criteria in Solid Tumours (RECIST) version. 1.1, and iRECIST on study population
Determine the effect of RegoNivo on; QoL - EORTC Quality of Life Questionnaire
Quality of life (QoL)(scores from participant-completed questionnaires) of participants on study EORTC QLQ-C30: Q1 - Q28, Min 1 Max 4, Higher Score = Worse
Determine the effect of RegoNivo on; QoL - EORTC Quality of Life Questionnaire
Quality of life (QoL)(scores from participant-completed questionnaires) of participants on study EORTC QLQ-C30: Q29 & Q30 Min 1 Max 7, Higher = Better
Determine the effect of RegoNivo on; QoL - EORTC Quality of Life Questionnaire -Stomach Cancer
Quality of life (QoL)(scores from participant-completed questionnaires) of participants on study EORTC QLQ STO22 Min 1 Max 4, Higher Score = Worse
Determine the effect of RegoNivo on; QoL - Patient D.A.T.A form (self assessment of pain on health aspect)
Quality of life (QoL)(scores from participant-completed questionnaires) of participants on study Patient D.A.T.A Form: Q1 - Q17 Min 0 Max 10, Higher Score = Worse
Determine the effect of RegoNivo on; QoL - Patient D.A.T.A form (self rating on health aspects)
Quality of life (QoL)(scores from participant-completed questionnaires) of participants on study Patient D.A.T.A Form: Q18 - Q24 Min 0 Max 10, Higher Score = Better
Determine the effect of RegoNivo on; QoL - Patient D.A.T.A form (health aspect impact self assessment)
Quality of life (QoL)(scores from participant-completed questionnaires) of participants on study Patient D.A.T.A Form: Q25 - Q47 Min 0 Max 10, Higher Score = Worse
Determine the effect of RegoNivo on; QoL - Health Questionnaire
Quality of life (QoL)(scores from participant-completed questionnaires) of participants on study EQ-5D-5L Health questionnaire Min 0 Max 100, Higher Score = Better
Determine the effect of RegoNivo on; Safety
Safety (rates of adverse events) of participants on study

Full Information

First Posted
February 24, 2021
Last Updated
October 10, 2023
Sponsor
Australasian Gastro-Intestinal Trials Group
Collaborators
Bayer, Bristol-Myers Squibb, University of Sydney, Academic and Community Cancer Research United, Taiwanese Cooperative Oncology Group, Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, National Cancer Center Hospital East, Syneos Health
search

1. Study Identification

Unique Protocol Identification Number
NCT04879368
Brief Title
RegoNivo vs Standard of Care Chemotherapy in AGOC
Acronym
INTEGRATEIIb
Official Title
A Randomised Phase III Open Label Study of Regorafenib + Nivolumab vs Standard Chemotherapy in Refractory Advanced Gastro-Oesophageal Cancer (AGOC)
Study Type
Interventional

2. Study Status

Record Verification Date
October 2023
Overall Recruitment Status
Recruiting
Study Start Date
June 1, 2021 (Actual)
Primary Completion Date
June 1, 2025 (Anticipated)
Study Completion Date
June 1, 2026 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Australasian Gastro-Intestinal Trials Group
Collaborators
Bayer, Bristol-Myers Squibb, University of Sydney, Academic and Community Cancer Research United, Taiwanese Cooperative Oncology Group, Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, National Cancer Center Hospital East, Syneos Health

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
To determine if the regorafenib and nivolumab combination (RegoNivo) improves overall survival compared with current standard chemotherapy options in refractory AGOC.
Detailed Description
The purpose of this international study is to determine if the combination of regorafenib and nivolumab is more effective than standard chemotherapy in prolonging overall survival in a broad group of participants with AGOC, who have progressed after treatment with standard anti-cancer therapy. In the INTEGRATE study, regorafenib alone was shown to be effective in prolonging the progression-free period in people with AGOC following standard anti-cancer therapy (i.e. it delayed tumour growth), and demonstrated a potential benefit on long term survival. Recent research has shown the early results from this combination of regorafenib & nivolumab may improve outcomes for cancer patients. INTEGRATE IIb will investigate this effect further in a larger group of participants with AGOC. The study aims to determine: i. Whether the combination of regorafenib/nivolumab is likely to help patients with AGOC live longer; ii. The effects of this treatment on progression-free survival; iii. The numbers of participants responding to the treatment iv. The effects of this treatment on quality of life v. The side effects and tolerability of this treatment vi. Molecular differences (e.g. variations in genes or proteins) that may account for the effects of this treatment vii. Differences in the costs of care for people on this treatment. The Investigators plan to enrol 450 participants in the study from, but not limited to; Australia, New Zealand, South Korea, Japan, Taiwan, Canada, USA, Germany, Belgium, Spain, France, Switzerland, Netherlands and Italy.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Gastro-Oesophageal Cancer
Keywords
Metastatic, Locally recurrent, Oesophago-gastric junction, Stomach, Adenocarcinoma, Undifferentiated carcinoma, RegoNivo

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Model Description
Parallel assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
450 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
RegoNivo
Arm Type
Experimental
Arm Description
Participants in the RegoNivo arm will; self-administer 90mg (3x30mg) of regorafenib days 1-21 of each 28-day treatment cycle and; receive intravenous nivolumab 240 mg day 1 of each 14 day cycle until disease progression or prohibitive adverse events as per protocol, given in hospital by infusion. After 2 months, patients whose disease is controlled may have nivolumab administered 480 mg every 28 days.
Arm Title
Standard of Care
Arm Type
Active Comparator
Arm Description
Participants in the control arm will receive investigator choice chemotherapy with any of the following agents taxane (paclitaxel or docetaxel) irinotecan or oral trifluridine/tipiracil (TAS102) All treatment groups will receive Best Supportive Care (BSC).
Intervention Type
Drug
Intervention Name(s)
Regorafenib
Other Intervention Name(s)
Stivarga
Intervention Description
Oral multi-targeted tyrosine kinase inhibitor (TKI) which targets angiogenic (VEGF, TIE-2), stromal (PDGF-β), and oncogenic (RAF, RET and KIT) receptor tyrosine kinases
Intervention Type
Biological
Intervention Name(s)
Nivolumab
Other Intervention Name(s)
Opdivo
Intervention Description
human IgG4 monoclonal antibody inhibitor of PD-1
Intervention Type
Drug
Intervention Name(s)
Docetaxel
Other Intervention Name(s)
Taxotere
Intervention Description
Docetaxel is taxane-derivative chemotherapy drug, used in the treatment of early, locally advanced and metastatic breast cancer. It is an anti-microtubule agent. Other uses are in the treatment of non-small cell lung cancer, advanced stomach cancer, head and neck cancers, soft tissue sarcoma, ovarian cancer, metastatic prostate cancer, etc. microtubules, and simultaneously promotes assembly and inhibits disassembly of them
Intervention Type
Drug
Intervention Name(s)
Paclitaxel
Other Intervention Name(s)
Abraxane
Intervention Description
Paclitaxel is one of several cytoskeletal drugs that target tubulin. Paclitaxel-treated cells have defects in mitotic spindle assembly, chromosome segregation, and cell division. Unlike other tubulin-targeting drugs, such as colchicine, that inhibit microtubule assembly, paclitaxel stabilizes the microtubule polymer and protects it from disassembly. Chromosomes are thus unable to achieve a metaphase spindle configuration. This blocks the progression of mitosis and prolonged activation of the mitotic checkpoint triggers apoptosis or reversion to the G0-phase of the cell cycle without cell division
Intervention Type
Drug
Intervention Name(s)
Irinotecan
Other Intervention Name(s)
Camptosar
Intervention Description
Camptothecin, one of the four major structural classifications of plant-derived anti-cancerous compounds, is a cytotoxic alkaloid which consists of a pentacyclic ring structure containing a pyrrole (3, 4 β) quinoline moiety, an S-configured lactone form, and a carboxylate form. Irinotecan is activated by hydrolysis to SN-38, an inhibitor of topoisomerase I. This is then inactivated by glucuronidation by uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1). The inhibition of topoisomerase I by the active metabolite SN-38 eventually leads to inhibition of both DNA replication and transcription.
Intervention Type
Drug
Intervention Name(s)
Trifluridine/Tipracil
Other Intervention Name(s)
Lonsurf
Intervention Description
The drug consists of the cytotoxin trifluridine and the thymidine phosphorylase inhibitor (TPI) tipiracil. Trifluridine is incorporated into DNA during DNA synthesis and inhibits tumor cell growth. Trifluridine (TFT) is incorporated into DNA by phosphorylation by thymidylate kinase (TK) to TF-TMP; TF-TMP then covalently binds to tyrosine 146 of the active site of thymidylate synthase (TS) inhibiting the enzyme's activity. TS is vital to the synthesis of DNA because it is an enzyme involved in the synthesis of the deoxynucleotide, thymidine triphosphate (dTTP). Inhibition of TS depletes the cell of dTTP and causes accumulation of deoxyuridine monophosphate (dUMP), which increases the likelihood that uracil gets misincorporated into the DNA.
Primary Outcome Measure Information:
Title
O/S
Description
To determine the effect of RegoNivo on overall survival (OS) (death from any cause) in the overall study population and in the Asian sub-population.
Time Frame
5 years
Secondary Outcome Measure Information:
Title
Determine the effect of RegoNivo on; PFS
Description
Progression free survival (PFS)(disease progression or death) in the study population
Time Frame
5 years
Title
Determine the effect of RegoNivo on; OTRR
Description
Objective tumour response rate (OTRR)((partial or complete response (PR or CR)) according to Response Evaluation Criteria in Solid Tumours (RECIST) version. 1.1, and iRECIST on study population
Time Frame
5 years
Title
Determine the effect of RegoNivo on; QoL - EORTC Quality of Life Questionnaire
Description
Quality of life (QoL)(scores from participant-completed questionnaires) of participants on study EORTC QLQ-C30: Q1 - Q28, Min 1 Max 4, Higher Score = Worse
Time Frame
5 years
Title
Determine the effect of RegoNivo on; QoL - EORTC Quality of Life Questionnaire
Description
Quality of life (QoL)(scores from participant-completed questionnaires) of participants on study EORTC QLQ-C30: Q29 & Q30 Min 1 Max 7, Higher = Better
Time Frame
5 years
Title
Determine the effect of RegoNivo on; QoL - EORTC Quality of Life Questionnaire -Stomach Cancer
Description
Quality of life (QoL)(scores from participant-completed questionnaires) of participants on study EORTC QLQ STO22 Min 1 Max 4, Higher Score = Worse
Time Frame
5 years
Title
Determine the effect of RegoNivo on; QoL - Patient D.A.T.A form (self assessment of pain on health aspect)
Description
Quality of life (QoL)(scores from participant-completed questionnaires) of participants on study Patient D.A.T.A Form: Q1 - Q17 Min 0 Max 10, Higher Score = Worse
Time Frame
5 years
Title
Determine the effect of RegoNivo on; QoL - Patient D.A.T.A form (self rating on health aspects)
Description
Quality of life (QoL)(scores from participant-completed questionnaires) of participants on study Patient D.A.T.A Form: Q18 - Q24 Min 0 Max 10, Higher Score = Better
Time Frame
5 years
Title
Determine the effect of RegoNivo on; QoL - Patient D.A.T.A form (health aspect impact self assessment)
Description
Quality of life (QoL)(scores from participant-completed questionnaires) of participants on study Patient D.A.T.A Form: Q25 - Q47 Min 0 Max 10, Higher Score = Worse
Time Frame
5 years
Title
Determine the effect of RegoNivo on; QoL - Health Questionnaire
Description
Quality of life (QoL)(scores from participant-completed questionnaires) of participants on study EQ-5D-5L Health questionnaire Min 0 Max 100, Higher Score = Better
Time Frame
5 years
Title
Determine the effect of RegoNivo on; Safety
Description
Safety (rates of adverse events) of participants on study
Time Frame
5 years
Other Pre-specified Outcome Measures:
Title
Prognostic biomarker identification for AGOC
Description
To identify prognostic and predictive biomarkers (tissue and circulating) for study endpoints (relating to survival, response and safety).
Time Frame
Up to 24 months following close of study.
Title
Regorafenib max plasma concentration level assessment (Cmax) across geographical regions
Description
To evaluate regorafenib Cmax in patient populations from different geographical regions (regorafenib levels).
Time Frame
Up to 24 months following close of study.
Title
Regorafenib levels and correlation to treatment
Description
To evaluate regorafenib levels and their correlation to outcomes in treatment
Time Frame
Up to 24 months following close of study.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Adults (18 years or over) with metastatic or locally recurrent gastro-oesophageal cancer which: has arisen in any primary gastro-oesophageal site (oesophago-gastric junction (GOJ) or stomach); and is of adenocarcinoma or undifferentiated carcinoma histology; and is evaluable according to Response Evaluation Criteria in Solid Tumours (RECIST Version 1.1) by computed tomography (CT) scan performed within 21 days prior to randomisation. A lesion in a previously irradiated area is eligible to be considered as measurable disease as long as there is objective evidence of progression of the lesion prior to study enrolment; and has failed or been intolerant to a minimum of 2 lines of prior anti-cancer therapy for recurrent/metastatic disease which must have included at least one platinum agent and one fluoropyrimidine analogue. Note: Neoadjuvant or adjuvant chemotherapy or chemoradiotherapy will be considered as first line treatment where people have relapsed or progressed within 6 months of completing treatment; Radiosensitising chemotherapy given solely for this purpose concurrent with palliative radiation will not be considered as a line of treatment. Ramucirumab monotherapy, or immunotherapy with a checkpoint inhibitor, will be considered a line of treatment. HER2-positive participants must have received trastuzumab Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1 (Appendix 1). Ability to swallow oral medication. Adequate bone marrow function (Platelets ≥100x109/L; Absolute Neutrophil Count (ANC) ≥1.5x109/L and Haemoglobin ≥ 9.0g/dL). Adequate renal function (Creatinine clearance >50 ml/min) based on either the Cockcroft-Gault formula (Appendix 2), 24-hour urine or Glomerular Filtration Rate (GFR) scan; and serum creatinine ≤1.5 x Upper Limit of Normal (ULN). Adequate liver function (Serum total bilirubin ≤1.5 x ULN, and INR ≤ 1.5 x ULN, and Alanine aminotransferase (ALT), Aspartate aminotransferase (AST), Alkaline phosphatase (ALP) ≤2.5 x ULN (≤ 5 x ULN for participants with liver metastases)). Participants being treated with an anti-coagulant, such as warfarin or heparin, will be allowed to participate provided that no prior evidence of an underlying abnormality in these parameters exists. Willing and able to comply with all study requirements, including treatment, timing, and/or nature of required assessments and follow-up. Study treatment both planned and able to start within 7 days after randomisation (note: subjects randomised on a Friday should commence treatment no earlier than the following Monday) Signed, written informed consent Exclusion Criteria: Known allergy to the investigational product drug class or excipients in the regorafenib and/or nivolumab Poorly-controlled hypertension (systolic blood pressure >140mmHg or diastolic pressure> 90mmHg despite optimal medical management). Participants with known, uncontrolled malabsorption syndromes Any prior anti-VEGF targeted therapy using small molecule VEGF TKIs (e.g. apatinib). Prior anti-VEGF targeted monoclonal antibody therapies (e.g. bevacizumab and ramucirumab) are permitted. Any prior use of more than one immune checkpoint inhibitor Treatment with any previous drug therapy within 2 weeks prior to first dose of study treatment. This includes any investigational therapy. Use of biological response modifiers, such as granulocyte colony stimulating factor (G-CSF), within 3 weeks prior to randomisation. Concurrent treatment with strong CYP3A4 inhibitors or inducers. Palliative radiotherapy, unless more than 14 days have elapsed between completion of radiation and the date of registration, and adverse events resulting from radiation have resolved to < Grade 2 according to CTCAE V5.0 Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to randomization Arterial thrombotic or ischaemic events, such as cerebrovascular accident, within 6 months prior to randomization. Venous thrombotic events and pulmonary embolism within 3 months prior to randomization Any haemorrhage or bleeding event ≥ Grade 3 according to CTCAE v5.0 within 4 weeks prior to randomization. Non-healing wound, ulcer, or bone fracture. Interstitial lung disease with ongoing signs and symptoms Clinical hyperthyroidism or hypothyroidism. Note: non-clinically significant abnormal TFTs (abnormal TSH and abnormal T3 and/or abnormal T4) considered to be due to sick euthyroid syndrome is allowed. Persistent proteinuria of ≥ Grade 3 according to CTCAE v5.0 (equivalent to > 3.5g of protein over 24 hour measured on either a random specimen or 24 hour collection. Uncontrolled metastatic disease to the central nervous system. To be eligible, known CNS metastases should have been treated with surgery and/or radiotherapy and the patient should have been receiving a stable dose of steroids for at least 2 weeks prior to randomization, with no deterioration in neurological symptoms during this time. History of another malignancy within 2 years prior to randomization. Participants with the following are eligible for this study: curatively treated cervical carcinoma in situ, non-melanomatous carcinoma of the skin, superficial bladder tumours (T1a [Non-invasive tumour], and Tis [Carcinoma in situ]), treated thyroid papillary cancer Any significant active infection, including chronic active hepatitis B, hepatitis C, or HIV. Testing for these is not mandatory unless clinically indicated. Participants with known Hepatitis B/C infection will be allowed to participate providing evidence of viral suppression has been documented and the patient remains on appropriate anti-viral therapy. Patients with acute coronary syndrome (including myocardial infarction and unstable angina), and with a history of coronary angioplasty or stent placement performed within 6 months before enrolment Patients with a ≥ grade 3 active infection according to CTCAE version 5.0 Patients with concurrent autoimmune disease, or a history of chronic or recurrent autoimmune disease Patients who require systemic corticosteroids (excluding temporary usage for tests, prophylactic administration for allergic reactions, or to alleviate swelling associated with radiotherapy; if used as replacement therapy e.g. ≤ 10 mg prednisolone or dexamethasone ≤ 2 mg per day) or immunosuppressants, or who have received such a therapy < 14 days prior to randomisation Patients with a seizure disorder who require pharmacotherapy Serious medical or psychiatric condition(s) that might limit the ability of the patient to comply with the protocol. Pregnancy, lactation, or inadequate contraception. Women must be post-menopausal infertile, or use a reliable means of contraception. Women of childbearing potential must have a negative pregnancy test done within 7 days prior to randomization. Men must have been surgically sterilized or use a barrier method of contraception.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Clinical Project Manager
Phone
02 9562 5339
Email
integrateii.study@sydney.edu.au
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Nick Pavlakis, Prof
Organizational Affiliation
AGITG
Official's Role
Study Chair
Facility Information:
Facility Name
Mayo Clinic Arizona
City
Scottsdale
State/Province
Arizona
ZIP/Postal Code
85054
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Mohamad B. Sonbol
Facility Name
USC Norris
City
Los Angeles
State/Province
California
ZIP/Postal Code
90001
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Syma Iqbal
Facility Name
Siouxland Regional Cancer Center
City
Sioux City
State/Province
Iowa
ZIP/Postal Code
51101
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Donald Wender
Facility Name
Monument Health Rapid City Hospital
City
Rapid City
State/Province
South Dakota
ZIP/Postal Code
57701
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Abdel-Ghani Azzouqa
Facility Name
Fred Hutchinson Cancer Research Centre - South Lake Union Clinic
City
Seattle
State/Province
Washington
ZIP/Postal Code
98109
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
David Zhen
Facility Name
Coffs Harbour Health Campus
City
Coffs Harbour
State/Province
New South Wales
ZIP/Postal Code
2450
Country
Australia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Trial Coordinator
Phone
+61 2 9562 5000
Email
INTEGRATEII.study@sydney.edu.au
First Name & Middle Initial & Last Name & Degree
Karen Briscoe
Facility Name
Concord Repatriation General Hospital
City
Concord
State/Province
New South Wales
ZIP/Postal Code
2139
Country
Australia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Trial Coordinator
Phone
+61 2 9562 5000
Email
INTEGRATEII.study@sydney.edu.au
First Name & Middle Initial & Last Name & Degree
Kim Tam Bui
Facility Name
St Vincent's Public Hospital
City
Darlinghurst
State/Province
New South Wales
ZIP/Postal Code
2010
Country
Australia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Trial Coordinator
Phone
+61 2 9562 5000
Email
INTEGRATEII.study@sydney.edu.au
First Name & Middle Initial & Last Name & Degree
Hao-Wen Sim
Facility Name
Border Medical Oncology Research Unit
City
East Albury
State/Province
New South Wales
ZIP/Postal Code
2640
Country
Australia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Craig Underhill
Phone
+61 2956 25000
Email
INTEGRATEII.study@sydney.edu.au
First Name & Middle Initial & Last Name & Degree
Craig Underhill
Facility Name
Gosford Hospital
City
Gosford
State/Province
New South Wales
ZIP/Postal Code
2250
Country
Australia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Trial Coordinator
Phone
+61 2 9562 5000
Email
INTEGRATEII@ctc.usyd.edu.au
First Name & Middle Initial & Last Name & Degree
Matthew Wong
Facility Name
St George Hospital
City
Kogarah
State/Province
New South Wales
ZIP/Postal Code
2217
Country
Australia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Trial Coordinator
Phone
+61 2 9562 5000
Email
INTEGRATEII.study@sydney.edu.au
First Name & Middle Initial & Last Name & Degree
Katrin Sjoquist
Facility Name
Newcastle Private Hospital
City
New Lambton Heights
State/Province
New South Wales
ZIP/Postal Code
2035
Country
Australia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Trial Coordinator
Phone
+61 2 9562 5000
Email
INTEGRATEII.study@sydney.edu.au
First Name & Middle Initial & Last Name & Degree
Antonino Bonaventura
Facility Name
Port Macquarie Base Hospital
City
Port Macquarie
State/Province
New South Wales
ZIP/Postal Code
2444
Country
Australia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Trial Coordinator
Phone
+61 2 9562 5000
Email
INTEGRATEII.study@sydney.edu.au
First Name & Middle Initial & Last Name & Degree
Stephen Begbie
Facility Name
Prince of Wales Hospital
City
Randwick
State/Province
New South Wales
ZIP/Postal Code
2031
Country
Australia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Trial Coordinator
Phone
+61 2 9562 5000
Email
INTEGRATEII.study@sydney.edu.au
First Name & Middle Initial & Last Name & Degree
David Goldstein
Facility Name
Royal North Shore Private Hospital
City
Sydney
State/Province
New South Wales
ZIP/Postal Code
2065
Country
Australia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Trial Coordinator
Phone
+6129565000
Email
INTEGRATEII.study@sydney.edu.au
First Name & Middle Initial & Last Name & Degree
Nick Pavlakis
Facility Name
The Tweed Hospital
City
Tweed Heads
State/Province
New South Wales
ZIP/Postal Code
2485
Country
Australia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Trial Coordinator
Phone
+61 2 9562 5000
Email
INTEGRATEII.study@sydney.edu.au
First Name & Middle Initial & Last Name & Degree
Sumit Lumba
Facility Name
Ballarat Oncology and Haematology Services
City
Wendouree
State/Province
New South Wales
ZIP/Postal Code
3355
Country
Australia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Trial Coordinator
Phone
+61 2 9562 5000
Email
INTEGRATEII.study@sydney.edu.au
First Name & Middle Initial & Last Name & Degree
George Kannourakis
Facility Name
Westmead Hospital
City
Westmead
State/Province
New South Wales
ZIP/Postal Code
2145
Country
Australia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Trial Coordinator
Phone
+61 2 9562 5000
Email
INTEGRATEII.study@sydney.edu.au
First Name & Middle Initial & Last Name & Degree
Adnan Nagrial
Facility Name
Royal Darwin Hospital
City
Tiwi
State/Province
Northern Territory
ZIP/Postal Code
0810
Country
Australia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Trial Coordinator
Phone
+61 2 9562 5000
Email
INTEGRATEII.study@sydney.edu.au
First Name & Middle Initial & Last Name & Degree
Narayan Karanth
Facility Name
The Townsville Hospital
City
Douglas
State/Province
Queensland
ZIP/Postal Code
4814
Country
Australia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
INTEGRATE II Coordinator
Phone
+61 2 9562 5000
Email
INTEGRATEII.study@sydney.edu.au
First Name & Middle Initial & Last Name & Degree
Suresh Varma
Facility Name
Royal Brisbane and Womens Hospital
City
Herston
State/Province
Queensland
ZIP/Postal Code
4029
Country
Australia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Trial Coordinator
Phone
+61 2 9562 5000
Email
INTEGRATEII.study@sydney.edu.au
First Name & Middle Initial & Last Name & Degree
Matthew Burge
Facility Name
Sunshine Coast University Hospital
City
Sunshine Coast
State/Province
Queensland
ZIP/Postal Code
4560
Country
Australia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Trial Coordinator
Phone
+61 2 9562 5000
Email
INTEGRATEII.study@sydney.edu.au
First Name & Middle Initial & Last Name & Degree
Alessandra Francesconi
Facility Name
The Queen Elizabeth Hospital
City
Adelaide
State/Province
South Australia
ZIP/Postal Code
5011
Country
Australia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Trial Coordinator
Phone
+612956 5000
Email
INTEGRATEII.study@sydney.edu.au
First Name & Middle Initial & Last Name & Degree
Timothy Price
Facility Name
Flinders Medical Centre
City
Bedford Park
State/Province
South Australia
ZIP/Postal Code
5042
Country
Australia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Trial Coordinator
Phone
+61 2 9562 5000
Email
INTEGRATEII.study@sydney.edu.au
First Name & Middle Initial & Last Name & Degree
Chris Karapetis
Facility Name
Royal Hobart Hospital
City
Hobart
State/Province
Tasmania
ZIP/Postal Code
700
Country
Australia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Trial Coordinator
Phone
+61 2 9562 5000
Email
INTEGRATEII.study@sydney.edu.au
Facility Name
Monash Health
City
Clayton
State/Province
Victoria
ZIP/Postal Code
3168
Country
Australia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Trial Coordinator
Phone
+61 2956 5000
Email
INTEGRATEII.study@sydney.edu.au
First Name & Middle Initial & Last Name & Degree
Andrew Strickland
Facility Name
Austin Health
City
Melbourne
State/Province
Victoria
ZIP/Postal Code
3084
Country
Australia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Trial Coordinator
Phone
+61 2 9562 5000
Email
INTEGRATEII.study@sydney.edu.au
First Name & Middle Initial & Last Name & Degree
Niall Tebbutt
Facility Name
Sir Charles Gairdner Hospital
City
Nedlands
State/Province
Western Australia
ZIP/Postal Code
6009
Country
Australia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Trial Coordinator
Phone
+61 2 9562 5000
Email
INTEGRATEII.study@sydney.edu.au
First Name & Middle Initial & Last Name & Degree
Kevin Jasas
Facility Name
St John of God Hospital Subiaco
City
Subiaco
State/Province
Western Australia
ZIP/Postal Code
6008
Country
Australia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Trial Coordinator
Phone
+61 2 9562 5000
Email
INTEGRATEII.study@sydney.edu.au
First Name & Middle Initial & Last Name & Degree
Tom Van Hagen
Facility Name
Landeskrankenanstalten-Betriebsgesellschaft-KABEG
City
Klagenfurt
Country
Austria
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Wolfgang Eisterer
Facility Name
Ordensklinikum Linz GmbH Barmherzige schwestern
City
Linz
Country
Austria
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Holger Florian Rumpold
Facility Name
Medizinische Universitaet Wien
City
Vienna
Country
Austria
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ayseguel Ilhan-Mutlu
Facility Name
Landesklinikum Wiener Neustadt
City
Wiener Neustadt
Country
Austria
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Birgit Gruenberger
Facility Name
Evang. Klinikum Bethel Bielefeld
City
Gütersloh
State/Province
Nordrhein-Westfalen
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Kambiz Taghizadeh
Facility Name
Helios Bad Saarow
City
Bad Saarow
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Daniel Pink
Facility Name
Klinikum Bayreuth
City
Bayreuth
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Alexander Kiani
Facility Name
Charité Universitätsmedizin Berlin
City
Berlin
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Peter Thuss-Patience
Facility Name
Universitätsklinikum Bonn
City
Bonn
Country
Germany
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Maria Gonzalez-Carmona
Facility Name
KEM/Evang. Kliniken Essen Mitte gGmbH
City
Essen
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Christian Müller
Facility Name
Institut für Klinisch Onkol Forschung am Krankenhaus Nordwest
City
Frankfurt
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Thorsten Goetze
Facility Name
Universitätsklinikum Greifswald
City
Greifswald
Country
Germany
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ali Aghdassi
Facility Name
Norddeutsches Studienzentrum für Innovative Onkologie (NIO)
City
Hamburg
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Eray Gökkurt
Facility Name
Universitätsklinikum Heidelberg
City
Heidelberg
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Georg Martin Haag
Facility Name
Universitätsklinikum Jena
City
Jena
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Udo Lindig
Facility Name
Kliniken der Stadt Köln
City
Koeln
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Stefan Angermeier
Facility Name
Universitätsklinikum Leipzig
City
Leipzig
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Gertraud Stocker
Facility Name
Klinikum Leverkusen gGmbH
City
Leverkusen
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Andrea Heider
Facility Name
Klinikum Ludwigburg
City
Ludwigsburg
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Bernhard Sibbing
Facility Name
Klinikum Magdeburg gGmbH
City
Magdeburg
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Christoph Kahl
Facility Name
Universitätsklinikum Mainz
City
Mainz
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Markus Möhler
Facility Name
Philipps-Universitat Marburg
City
Marburg
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jorge Riera Knorrenschild
Facility Name
Klinikum rechts der Isar der TU München
City
München
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sylvie Lorenzen
Facility Name
Studienzentrum Onkologie Ravensburg
City
Ravensburg
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Tobais Dechow
Facility Name
Caritas Klinikum Saarbrücken St. Theresia
City
Saarbrücken
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Manfred P. Lutz
Facility Name
Universitätsklinikum Ulm
City
Ulm
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Thomas Ettrich
Facility Name
Istituto Nazionale Tumori di Napoli-IRCCS Fondazione G. Pascale
City
Napoli
Country
Italy
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Antonio Avallone
Facility Name
Universitae degli studi della Campania "Luigi Vanvitelli"
City
Napoli
Country
Italy
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ferdinando De Vita
Facility Name
Azienda USL-IRCCS Di Reggio Emilia
City
Reggio Emilia
Country
Italy
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Angela Damato
Facility Name
San Camillo Forlanini Hospitals
City
Roma
Country
Italy
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Carlo Garufi
Facility Name
Universita Cattolica del Sacro Cuore, University Hospital Gemelli
City
Roma
Country
Italy
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Carmelo Pozzo
Facility Name
IRCCS Fondazione Casa Sollievo della Sofferenza
City
San Giovanni Rotondo
Country
Italy
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Evaristo Maiello
Facility Name
National Cancer Centre Hospital East
City
Chiba
State/Province
Kashiwa
Country
Japan
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Kohei Shitara
Facility Name
Hokkaido University Hospital
City
Sapporo
State/Province
Kita
Country
Japan
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Yoshito Komatsu
Facility Name
Kyushu Cancer Center
City
Fukuoka
Country
Japan
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Taito Esaki
Facility Name
Shikoku Cancer Center
City
Matsuyama
Country
Japan
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Tomohiro Nishina
Facility Name
Saitama Cancer Center
City
Saitama
Country
Japan
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Hiroki Hara
Facility Name
Shizuoka Cancer Center
City
Shizuoka
Country
Japan
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Hirofumi Yasui
Facility Name
Hallym University Sacred Heart Hospital
City
Anyang
Country
Korea, Republic of
Individual Site Status
Completed
Facility Name
Dong-A University Hospital
City
Busan
Country
Korea, Republic of
Individual Site Status
Completed
Facility Name
Haeundae Paik Hospital
City
Busan
Country
Korea, Republic of
Individual Site Status
Active, not recruiting
Facility Name
Chungbuk National University Hospital
City
Cheongju
Country
Korea, Republic of
Individual Site Status
Active, not recruiting
Facility Name
Jeonbuk National University Hospital
City
Jeonju
Country
Korea, Republic of
Individual Site Status
Active, not recruiting
Facility Name
Gyeongsang National University Hospital
City
Jinju
Country
Korea, Republic of
Individual Site Status
Active, not recruiting
Facility Name
Asan Medical Centre
City
Seoul
Country
Korea, Republic of
Individual Site Status
Active, not recruiting
Facility Name
Chung-Ang University Hospital
City
Seoul
Country
Korea, Republic of
Individual Site Status
Active, not recruiting
Facility Name
Kangbuk Samsung Hospital
City
Seoul
Country
Korea, Republic of
Individual Site Status
Active, not recruiting
Facility Name
Korea University Anam Hospital
City
Seoul
Country
Korea, Republic of
Individual Site Status
Active, not recruiting
Facility Name
Korea University Guro Hospital
City
Seoul
Country
Korea, Republic of
Individual Site Status
Active, not recruiting
Facility Name
Seoul National University Bundang Hospital
City
Seoul
Country
Korea, Republic of
Individual Site Status
Active, not recruiting
Facility Name
Seoul National University Hospital
City
Seoul
Country
Korea, Republic of
Individual Site Status
Active, not recruiting
Facility Name
SMG-SNU Boramae Medical Center
City
Seoul
Country
Korea, Republic of
Individual Site Status
Completed
Facility Name
The Catholic University of Korea - Seoul St. Mary's Hospital
City
Seoul
Country
Korea, Republic of
Individual Site Status
Active, not recruiting
Facility Name
The Catholic University of Korea - Yeouido St. Mary's Hospital
City
Seoul
Country
Korea, Republic of
Individual Site Status
Active, not recruiting
Facility Name
Yonsei University Health System - Gangnam Severance Hospital
City
Seoul
Country
Korea, Republic of
Individual Site Status
Active, not recruiting
Facility Name
Yonsei University Health System - Severance Hospital
City
Seoul
Country
Korea, Republic of
Individual Site Status
Active, not recruiting
Facility Name
Vall d'Hebron University Hospital
City
Barcelona
Country
Spain
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Marc Diez
Facility Name
Hospital Universitario de Navarra
City
Pamplona
Country
Spain
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Maria Alsina
Facility Name
Hospital Clinico Universitario De Valencia
City
Valencia
Country
Spain
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Tania Fleitas
Facility Name
Kaohsiung Medical University Chung-Ho Memorial Hospital
City
Kaohsiung
Country
Taiwan
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jaw-Yuan Wang
Facility Name
China Medical University Hospital (CMUH)
City
Taichung
Country
Taiwan
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Li-Yuan Bai
Facility Name
National Cheng Kung University Hospital
City
Taipei
Country
Taiwan
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Li-Tzong Chen
Facility Name
National Taiwan University Hospital (NTUH)
City
Taipei
Country
Taiwan
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Kun-Huei Yeh
Facility Name
Taipei Veterans General Hospital (TPVGH)
City
Taipei
Country
Taiwan
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Yi-Ping Hung

12. IPD Sharing Statement

Learn more about this trial

RegoNivo vs Standard of Care Chemotherapy in AGOC

We'll reach out to this number within 24 hrs